What a GLP-1 Weight-Loss Consent Form Should Include
What a GLP-1 Weight-Loss Consent Form Should Include
If your clinic prescribes semaglutide or tirzepatide for weight management, documented informed consent is not optional paperwork — it's the record that shows the patient understood the treatment, its risks, and their alternatives. Here's exactly what a compliant GLP-1 consent form should capture, and a ready-to-fill template if you'd rather not build one from scratch.
GLP-1 receptor agonists such as semaglutide and dual GIP/GLP-1 agents such as tirzepatide have moved weight management to the center of many med spas, telehealth practices, and physician-supervised clinics. With that growth comes scrutiny. A clear GLP-1 consent form is the document that demonstrates you disclosed the material risks, confirmed the patient was an appropriate candidate, and gave them the chance to ask questions before treatment began.
This guide walks a licensed provider through every section a solid GLP-1 weight-loss consent form should document. It describes what the form should record — it is not clinical guidance, and it does not tell you how to prescribe. Use the checklist to build your own, or start from a template and adapt it with your medical director.
The short version: Identify the patient and their history → explain how the medication works and that it's for weight management → state the intended results and that they vary → disclose the risks and side effects, including the thyroid boxed warning → note alternatives and compounded-vs-approved product → cover aftercare, monitoring, and questions answered → capture dated signatures. That's a complete informed-consent record.
What a GLP-1 consent form should document
Think of the form as the written proof of a real informed-consent conversation. At minimum, a GLP-1 weight-loss consent form should document these elements:
- Patient identification and medical history. Patient name and date of birth, current medications, allergies, relevant conditions, and — importantly for this drug class — any personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2), plus history of pancreatitis, gallbladder disease, or diabetic retinopathy.
- How GLP-1 medications work, in general terms. A plain-language explanation that the medication mimics a gut hormone that helps regulate appetite and blood sugar and slows gastric emptying.
- That it may be prescribed for weight management. A note of the intended use in this patient, including where use may be outside a product's FDA-approved labeling and what that means.
- Intended results — and that they vary. A statement that individual results differ, that the medication supports (not replaces) diet and lifestyle changes, and that no specific amount of weight loss is guaranteed.
- Risks and side effects to disclose. Common gastrointestinal effects (nausea, vomiting, diarrhea, constipation), the risk of pancreatitis and gallbladder problems, possible injection-site reactions, hypoglycemia risk when combined with certain other medications, and the FDA boxed warning regarding the risk of thyroid C-cell tumors with the associated MTC/MEN2 contraindication.
- Pregnancy and reproductive caution. A statement that the medication is generally not recommended during pregnancy or while trying to conceive, and guidance to inform the provider of pregnancy or breastfeeding status.
- Alternatives. Acknowledgment that other options exist — lifestyle programs, other medications, or no treatment — and that the patient may decline.
- Compounded vs. FDA-approved product. Where a compounded formulation is used, a clear disclosure that it is not an FDA-approved finished drug product and what that distinction means for the patient.
- Aftercare and monitoring. Follow-up cadence, dose-titration expectations, warning signs that require immediate care, and how to reach the clinic.
- Questions answered and signatures. Confirmation that the patient's questions were answered and they consented voluntarily, with dated signature lines for the patient and the treating or supervising provider.
Why documented informed consent matters for weight-loss programs
Informed consent is both an ethical duty and a risk-management tool. For a medication class carrying a boxed warning and a defined contraindication, the consent form is where you show that the patient was screened for MTC/MEN2 history, understood the gastrointestinal and pancreatitis risks, and chose treatment anyway. A well-documented form protects the patient's understanding and protects your practice if an outcome is ever questioned. It also standardizes the conversation so every patient in your program receives the same disclosures.
Telehealth considerations
Many GLP-1 weight-loss programs run partly or entirely by telehealth. Those visits generally require the same informed consent as in-person care, and many states also require separate consent to be treated via telehealth. If your intake is remote, make sure the form can be reviewed and signed electronically, that it captures the same history and risk disclosures, and that it reflects any state-specific telehealth requirements. A good bundle pairs the GLP-1 consent with a telehealth consent and an intake form so the remote workflow is complete.
Record-keeping
A signed consent form only helps if you can produce it later. Store the completed form in the patient's chart, keep it for the retention period your state and payers require, and version your template so you can show which disclosures were in effect on the date of service. Whenever labeling, warnings, or your protocols change, update the template and note the revision date.
Skip the blank page. Our editable GLP-1 Weight Loss Consent Form template already includes the history screening, risk disclosures, boxed-warning language, and signature blocks above as fillable fields — type your clinic details straight into the PDF, or send it for e-signature. It's also part of the full Med Spa & Injector Forms Bundle (19 forms including GLP-1, telehealth consent, intake, and a good-faith exam) if you want the whole weight-loss and injectables workflow in one download.
Consent form vs. intake form: you likely need both
They do different jobs. An intake form gathers the patient's history, medications, and goals so you can assess candidacy. A consent form records that, once assessed, the patient understood the specific treatment and its risks and agreed to proceed. Most weight-loss programs collect intake first, then obtain consent before the first dose — and telehealth practices frequently add a separate telehealth consent alongside both.
A quick word on compliance
A well-built template covers the standard disclosures for a physician-supervised GLP-1 weight-loss program, but it is general information, not medical or legal advice. Scope-of-practice, supervision, and informed-consent rules vary by state, and the appropriate disclosures depend on the specific product you use and the patient in front of you. Have your GLP-1 consent form reviewed by your medical director and attorney before you put it into clinical use.
Get the fillable GLP-1 Consent Form
Every element in this guide, as an editable PDF you can brand, fill in, and reuse for every patient. Instant download, print-ready in US Letter and A4.
Get the template on Etsy →Disclaimer: EsthiDocs provides customizable templates for licensed professionals for general informational purposes only. This article and our templates are not medical or legal advice. You are responsible for compliance with your state's scope-of-practice and informed-consent laws; have all forms reviewed by your medical director and attorney before clinical use.
Comments
Post a Comment